Lataa...
Guselkumab, an anti‐interleukin‐23 monoclonal antibody, for the treatment of moderate to severe plaque‐type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double‐blind, placebo‐controlled study
Previous global studies of guselkumab have demonstrated clinical benefits in patients with psoriasis. The aim of this 52‐week, phase 3 study was to evaluate efficacy and safety of guselkumab in Japanese patients with moderate to severe plaque‐type psoriasis. Patients randomly received guselkumab 50...
Tallennettuna:
| Julkaisussa: | J Dermatol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6175099/ https://ncbi.nlm.nih.gov/pubmed/29905383 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1346-8138.14504 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|